Bishop confirmed as Genesis' executive chair
This article was originally published in Scrip
Executive Summary
After joining Genesis Biopharma's board of directors in January (scripintelligence.com, 13 January 2012), Hans Bishop has been made executive chair of the company, which is developing autologous cell therapies for the treatment of cancer. He replaces Anthony Cataldo who will remain on the board as a director. Mr Bishop joined Genesis after having served as chief operating officer of Dendreon.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.